<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The platelet-specific chemokine platelet factor 4 (<z:chebi fb="0" ids="30203">PF4</z:chebi>) is released in large amounts at sites of vascular injury </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="30203">PF4</z:chebi> binds to <z:chebi fb="5" ids="28304">heparin</z:chebi> with high affinity, but its in vivo biologic role has not been defined </plain></SENT>
<SENT sid="2" pm="."><plain>We studied the role of <z:chebi fb="0" ids="30203">PF4</z:chebi> in <z:mp ids='MP_0005048'>thrombosis</z:mp> using heterozygote and homozygote <z:chebi fb="0" ids="30203">PF4</z:chebi> knock-out mice (mPF4(+/-) and mPF4(-/-), respectively) and transgenic mice overexpressing human <z:chebi fb="0" ids="30203">PF4 </z:chebi>(hPF4(+)) </plain></SENT>
<SENT sid="3" pm="."><plain>None of these lines had an overt <z:hpo ids='HP_0001892'>bleeding diathesis</z:hpo>, but in a FeCl(3) carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> model, <z:hpo ids='HP_0000001'>all</z:hpo> showed impaired <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation </plain></SENT>
<SENT sid="4" pm="."><plain>This defect in <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation in the mPF4(-/-) animals was corrected by infusing hPF4 over a narrow concentration range </plain></SENT>
<SENT sid="5" pm="."><plain>The thrombotic defect in the mPF4(+/-) and mPF4(-/-) animals was particularly sensitive to infusions of the negatively charged <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> <z:chebi fb="5" ids="28304">heparin</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>However, the same amount of <z:chebi fb="5" ids="28304">heparin</z:chebi> paradoxically normalized <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation in the hPF4(+) animals, although these animals were anticoagulated systemically </plain></SENT>
<SENT sid="7" pm="."><plain>Upon infusion of the positively charged protein, protamine <z:chebi fb="0" ids="16189">sulfate</z:chebi>, the reverse was observed with mPF4(+/-) and mPF4(-/-) animals having improved <z:mp ids='MP_0005048'>thrombosis</z:mp>, with the hPF4(+) animals having worsened <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation </plain></SENT>
<SENT sid="8" pm="."><plain>These studies support an important role for <z:chebi fb="0" ids="30203">PF4</z:chebi> in <z:mp ids='MP_0005048'>thrombosis</z:mp>, and show that neutralization of <z:chebi fb="0" ids="30203">PF4</z:chebi> is an important component of <z:chebi fb="5" ids="28304">heparin</z:chebi>'s <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> effect </plain></SENT>
<SENT sid="9" pm="."><plain>The mechanisms underlying these observations of <z:chebi fb="0" ids="30203">PF4</z:chebi> biology and their clinical implications remain to be determined </plain></SENT>
</text></document>